• Edward A Copelan, Pamela Ann Crilley, Jeffrey Szer, Anthony J Dodds, Dustin Stevenson, Gary Phillips, Patrick Elder, Ian Nivison-Smith, Belinda R Avalos, Sam Penza, David Topolsky, Ronald Sobecks, Matt Kalaycio, and Brian J Bolwell.
• Department of Hematologic Oncology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA. copelae@ccf.org
• Biol. Blood Marrow Transplant. 2009 Jul 1; 15 (7): 851-5.

AbstractAllogeneic hematopoietic stem cell transplantation (HSCT) is the only known curative therapy for chronic myelogenous leukemia (CML). Failure, because of relapse or nonrelapse mortality (NRM), generally occurs within 3 years of transplantation, but large studies with long-term follow-up are limited. We present mature results in 335 patients with CML who underwent allogeneic bone marrow transplantation (BMT) from HLA-identical siblings following busulfan and cyclophosphamide (BU/Cy2). Two hundred twenty-nine were in chronic phase (CP) and 106 in accelerated or blastic phase at transplantation. Median follow-up exceeded 14 years. The estimated probability of 18-year leukemia-free survival (LFS) for CP patients was 55.6% and for those beyond CP, 10.5%. Of 182 patients who survived leukemia-free at 3 years, the estimated probability of LFS at 18 years was 61.9%. Late relapse (P = .039) and late NRM (P = .008) occurred at higher rates in patients beyond CP at transplantation. There was no plateau in LFS.

25 keywords...

hide…